FMP
Aptorum Group Limited
APM
NASDAQ
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
1.12 USD
0.01 (0.893%)
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
535.17k
911.51k
1.54M
1.3M
431.38k
492.64k
562.61k
642.51k
733.76k
837.97k
-
70.32
69.15
-15.95
-66.71
14.2
14.2
14.2
14.2
-15.12M
6.5M
-19.29M
-17.59M
-9.6M
-295.59k
-337.56k
-385.51k
-440.26k
-502.78k
-2.82k
712.93
-1.25k
-1.36k
-2.23k
-60
-60
-60
-60
-16.42M
5.16M
-20.48M
-18.8M
-10.72M
-295.59k
-337.56k
-385.51k
-440.26k
-502.78k
-3.07k
566.51
-1.33k
-1.45k
-2.49k
-60
-60
-60
-60
1.3M
1.33M
1.19M
1.21M
1.13M
463.61k
529.45k
604.64k
690.51k
788.58k
242.84
146.42
77.35
93.18
260.85
94.11
94.11
94.11
94.11
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)